Contact Us

Jain Lab

About Us

Participating Centers

Support Us

Contact us

Jain lab

Consortium Highlights & Events

Consortium Highlights & Events

May, 2025

PETAL Consortium Featured in ASCO Post!

We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.

Read more on: The ASCO Post

PETAL Consortium Featured in ASCO Post!

We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.

Read more on: The ASCO Post

PETAL Research Featured in Mass General Brigham News
Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.

Read the press release

PETAL Research Featured in Mass General Brigham News
Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.

Read the press release

Masschusets General Hospital logo

Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas - The PETAL Consortium’s latest paper published in the British Journal of Haematology.

Read the full paper

Masschusets General Hospital logo

Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas - The PETAL Consortium’s latest paper published in the British Journal of Haematology.

Read the full paper

We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!

We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!

We are delighted to congratulate Dhruv Mistry a key PETAL team member on earning his M.B.B.S. degree. We cannot wait to see his career unfold.

We are delighted to congratulate Dhruv Mistry a key PETAL team member on earning his M.B.B.S. degree. We cannot wait to see his career unfold.

April, 2025

Blood Cancers Today spoke with the PETAL sub-investigator, Mark Sorial on ‘What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?’

Read more

Blood Cancers Today spoke with the PETAL sub-investigator, Mark Sorial on ‘What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?’

Read more

We are thrilled to share that, Emmanuel Nwodo, has been awarded a prestigious Career Exploration and Development (CXD) grant from Bowdoin College for a 10 weeks internship with the PETAL Consortium. This grant will support his hands-on research experience with PETAL and culminate in a poster presentation, helping to advance his career in research and data science. Congratulations, Emmanuel!

We are thrilled to share that, Emmanuel Nwodo, has been awarded a prestigious Career Exploration and Development (CXD) grant from Bowdoin College for a 10 weeks internship with the PETAL Consortium. This grant will support his hands-on research experience with PETAL and culminate in a poster presentation, helping to advance his career in research and data science. Congratulations, Emmanuel!

March, 2025

Masschusets General Hospital logo

PETAL Consortium at the TCLF 2025 shared their ongoing projects and work through multiple compelling oral and poster presentations.

Masschusets General Hospital logo

PETAL Consortium at the TCLF 2025 shared their ongoing projects and work through multiple compelling oral and poster presentations.

Masschusets General Hospital logo

We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.

Read more

Masschusets General Hospital logo

We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.

Read more

February, 2025

Masschusets General Hospital logo

MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.

Read more

Masschusets General Hospital logo

MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.

Read more

Masschusets General Hospital logo

An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope

Read more

Masschusets General Hospital logo

An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope

Read more

January, 2025

Masschusets General Hospital logo

Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.

Read more

Masschusets General Hospital logo

Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.

Read more

Masschusets General Hospital logo

PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.

Read more

Masschusets General Hospital logo

PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.

Read more

We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment

We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment

PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.

PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.

December, 2024

November, 2024

The BROAD Institute joins PETAL as a genomics collaborator, bringing cutting-edge expertise to the consortium.

The BROAD Institute joins PETAL as a genomics collaborator, bringing cutting-edge expertise to the consortium.

September, 2024

PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment

PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment

August, 2024

Daiichi Sankyo Inc. and Kyowa Kirin join as the key sponsors to advance the future research at PETAL consortium

Daiichi Sankyo Inc. and Kyowa Kirin join as the key sponsors to advance the future research at PETAL consortium

July, 2024

Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.

Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.

June, 2024

PETAL Consortium @TCLF 2024 excited to share our work through many oral and poster presentations

Read more

PETAL Consortium @TCLF 2024 excited to share our work through many oral and poster presentations

Read more

May, 2024

Mark Sorial receives an educational grant from SecuraBio to develop novel machine learning models to estimate outcomes for patients with peripheral T-cell lymphoma.

Mark Sorial receives an educational grant from SecuraBio to develop novel machine learning models to estimate outcomes for patients with peripheral T-cell lymphoma.

February, 2024

PETAL Consortium’s first site Massachusetts General Hospital (MGH) is successfully activated for patient enrollment

PETAL Consortium’s first site Massachusetts General Hospital (MGH) is successfully activated for patient enrollment

December, 2023

The first PETAL Investigators meeting was held at ASH 2023 conference discussing the scope of PETAL and future of T-cell Lymphoma research.

The first PETAL Investigators meeting was held at ASH 2023 conference discussing the scope of PETAL and future of T-cell Lymphoma research.

Menu

About Us

Participating Centers

PIRT Calculator

Participating Sites Login

Contact Us

Support Us

Jain Lab

Study details

Our Study

Flow Chart

Study Synopsis

News center

Consortium Highlights & Events

Publications

Social Media

For healthcare professionals

PIRT Calculator

Participating Sites Login

@2024 PETAL Consortium • All rights reserved

Menu

About Us

Participating Centers

PIRT Calculator

Participating Sites Login

Contact Us

Support Us

Jain Lab

Study details

Our Study

Flow Chart

Study Synopsis

News center

Consortium Highlights & Events

Publications

Social Media

For healthcare professionals

PIRT Calculator

Participating Sites Login

@2024 PETAL Consortium • All rights reserved